About
Rare disease treatment
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Team (3)
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
484
By Phase
PHASE3: 2PHASE2: 4PHASE1: 1
By Status
COMPLETED: 2NOT_YET_RECRUITING: 1RECRUITING: 1ENROLLING_BY_INVITATION: 1WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07129759Lead Sponsor
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
PHASE3Not yet recruiting
150 participants
Started: Sep 30, 2026 · Completed: Feb 28, 2030
NCT06948214Lead Sponsor
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
PHASE3Recruiting
150 participants
Started: Oct 31, 2025 · Completed: Jan 31, 2028
NCT05796440Lead Sponsor
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
PHASE2Enrolling by invitation
60 participants
Started: Aug 1, 2023 · Completed: Apr 30, 2028
NCT05469490Collaborator
Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
PHASE1Withdrawn
Started: Oct 31, 2022 · Completed: Dec 31, 2026
NCT05250063Lead Sponsor
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
PHASE2Completed
18 participants
Started: Feb 18, 2022 · Completed: Jan 22, 2025
Locations (1)
Headquarters
Austin, TX, United States
Map
Loading map...